[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA894137B - Expression of retrovirus gag protein eukaryotic cells - Google Patents

Expression of retrovirus gag protein eukaryotic cells

Info

Publication number
ZA894137B
ZA894137B ZA894137A ZA894137A ZA894137B ZA 894137 B ZA894137 B ZA 894137B ZA 894137 A ZA894137 A ZA 894137A ZA 894137 A ZA894137 A ZA 894137A ZA 894137 B ZA894137 B ZA 894137B
Authority
ZA
South Africa
Prior art keywords
expression
eukaryotic cells
gag protein
retrovirus gag
protein eukaryotic
Prior art date
Application number
ZA894137A
Inventor
Eric Jacobs
Jacobs Eric
Dirk Gheysen
Gheysen Dirk
Original Assignee
Smithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Biolog filed Critical Smithkline Biolog
Publication of ZA894137B publication Critical patent/ZA894137B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA894137A 1988-06-03 1989-06-01 Expression of retrovirus gag protein eukaryotic cells ZA894137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20227188A 1988-06-03 1988-06-03

Publications (1)

Publication Number Publication Date
ZA894137B true ZA894137B (en) 1990-06-27

Family

ID=22749175

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA894137A ZA894137B (en) 1988-06-03 1989-06-01 Expression of retrovirus gag protein eukaryotic cells

Country Status (8)

Country Link
EP (1) EP0345242A3 (en)
AP (1) AP129A (en)
AU (2) AU627465B2 (en)
IL (1) IL90381A0 (en)
NZ (1) NZ229297A (en)
PT (1) PT90731A (en)
WO (1) WO1991000904A1 (en)
ZA (1) ZA894137B (en)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003794C (en) * 1988-12-01 2000-02-08 Hanne R. Johansen Expression of hiv proteins in drosophila cells
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
EP0907746B1 (en) 1996-04-05 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2001500738A (en) 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
DK0969862T3 (en) * 1997-02-07 2007-02-12 Merck & Co Inc Synthetic HIV gag genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE69838584T2 (en) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
AU2010699A (en) 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
ES2333071T5 (en) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Neisseria meningitidis antigens
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AR020318A1 (en) 1998-03-18 2002-05-08 Corixa Corp AN ISOLATED POLYNUCLEOTIDIC MOLECULA, AN ISOLATED POLYPEPTIDE CODIFIED BY THE MOLECULA, AN EXPRESSION VECTOR, A TRANSFORMED GUEST CELL, A FUSION PROTEIN, A PHARMACEUTICAL COMPOSITION AND A COMPREHENSIVE VACCINE; METHODS FOR TREATMENT, DETECTION,
BR9910089A (en) 1998-05-01 2004-06-08 Chiron Corp Compositions and antigens of neisseria meningitidis
AU5467899A (en) 1998-08-07 2000-02-28 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
EP2218733A1 (en) 1998-12-08 2010-08-18 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE69939599D1 (en) 1998-12-16 2008-10-30 Novartis Vaccines & Diagnostic HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
HUP0200760A2 (en) 1999-04-02 2002-06-29 Corixa Corp Compounds and methods for therapy and diagnosis of lung cancer
US8143386B2 (en) 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
BR0010130A (en) 1999-04-30 2002-06-04 Chiron Spa Preserved neisseria antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US7311922B1 (en) 1999-10-07 2007-12-25 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
PT2275551E (en) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Neisserial antigenic peptides
PT1232264E (en) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Human fgf-21 gene and gene expression products
ES2507100T3 (en) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. OMV vaccine supplemented against meningococcus
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
SI1265915T1 (en) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Novel compounds
PT1947187E (en) 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Hybrid expression of neisserial proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CA2409221C (en) 2000-05-19 2010-10-26 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2398391T3 (en) 2000-06-15 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Polynucleotides related to colon cancer
ES2374620T3 (en) 2000-06-20 2012-02-20 Corixa Corporation ANTIGEN MTB32A OF MYCOBACTERIUM TUBERCULOSIS WITH THE ACTIVE ACTIVE SITE AND FUSION PROTEINS OF THEMSELVES.
ATE396265T1 (en) 2000-06-28 2008-06-15 Corixa Corp COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
ES2397627T3 (en) 2000-12-07 2013-03-08 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses regulated by an increase in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003004657A1 (en) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002359446B2 (en) 2001-11-09 2008-12-04 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
ATE406912T1 (en) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic IMMUNIZATION AGAINST CHLAMYDIA TRACHEOMATIS
WO2003053220A2 (en) 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
PT1472375E (en) 2002-01-08 2009-05-19 Novartis Vaccines & Diagnostic Gene products differentially expressed in cancerous breast cells and their methods of use
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
WO2003080808A2 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
JP2005535308A (en) 2002-06-13 2005-11-24 カイロン コーポレイション HML-2 polypeptide expression vector
US7078041B2 (en) 2002-07-18 2006-07-18 University Of Washington Rapid, efficient purification of HSV-specific T-lymphocytes and HSV antigens identified via same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102746399B (en) 2002-12-24 2016-03-02 里纳特神经系统学公司 Anti-ngf antibodies and using method thereof
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
RU2389732C2 (en) 2003-01-06 2010-05-20 Корикса Корпорейшн Certain aminoalkyl glucosaminide phospahte derivatives and use thereof
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004073653A2 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
WO2005062955A2 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2848942B1 (en) 2004-07-14 2017-03-08 The Regents of The University of California Biomarkers for early detection of ovarian cancer
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
KR20070040824A (en) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptide and methods using same
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
CA2580103C (en) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
EP2392349A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
CA2604885A1 (en) 2005-04-07 2006-10-19 Guoying Yu Cacna1e in cancer diagnosis, detection and treatment
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2006117240A2 (en) 2005-04-29 2006-11-09 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating m tuberculosis infection
BRPI0613770A2 (en) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anti-cd26 antibodies and methods of use of these
LT2380592T (en) 2005-11-14 2018-05-10 Teva Pharmaceuticals International Gmbh Antagonist antibody directed against calcitonin gene-related peptide
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
EP2010226B1 (en) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2007146172A2 (en) 2006-06-07 2007-12-21 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
JP2010500399A (en) 2006-08-16 2010-01-07 ノバルティス アーゲー Immunogen from Urinary Pathogenic Escherichia coli
WO2008116116A2 (en) 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
EP3539567A1 (en) 2007-07-02 2019-09-18 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN106977601A (en) 2007-12-17 2017-07-25 辉瑞有限公司 The treatment of interstitial cystitis
CA2706502C (en) 2007-12-18 2018-08-07 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
CN102438650A (en) 2009-03-06 2012-05-02 诺华有限公司 Chlamydia antigens
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
PL2464658T3 (en) 2009-07-16 2015-03-31 Novartis Ag Detoxified escherichia coli immunogens
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP2013517772A (en) 2010-01-21 2013-05-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド A situation-specific gene screening platform to aid gene discovery and target confirmation
PL2528621T3 (en) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
TWI552760B (en) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 Antagonist anti-il-7 receptor antibodies and methods
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
JP2013533286A (en) 2010-07-30 2013-08-22 セントルイス ユニバーシティ How to treat pain
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2698635A3 (en) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
MX2013013627A (en) 2011-06-21 2014-04-25 Oncofactor Corp Compositions and methods for the therapy and diagnosis of cancer.
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
JP6078067B2 (en) 2011-08-29 2017-02-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of HDL-related molecules for the treatment and prevention of pro-inflammatory conditions
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
CA2954166A1 (en) 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
EP2794659A1 (en) 2011-12-22 2014-10-29 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
SG11201503245PA (en) 2012-11-09 2015-05-28 Pfizer Platelet-derived growth factor b specific antibodies and compositions and uses thereof
WO2014153258A2 (en) 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Improved thymidine kinase gene
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
KR102267292B1 (en) 2013-03-15 2021-06-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Mitochondrial-derived peptide mots3 regulated metabolism and cell survival
EP2970502A4 (en) 2013-03-15 2016-11-30 Dyax Corp Anti-plasma kallikrein antibodies
EP2986717A1 (en) 2013-04-19 2016-02-24 The Regents of The University of California Lone star virus
PE20151871A1 (en) 2013-05-07 2015-12-24 Rinat Neuroscience Corp ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE OF THEM
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
EP3695841A3 (en) 2013-07-01 2020-11-04 The Research Foundation for the State University of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN113683695A (en) 2013-08-02 2021-11-23 辉瑞公司 anti-CXCR 4 antibodies and antibody-drug conjugates
JP6740126B2 (en) 2013-11-13 2020-08-12 ファイザー・インコーポレイテッド Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
IL247853B (en) 2014-03-21 2022-08-01 Teva Pharmaceuticals Int Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3134546A4 (en) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
DK3143138T3 (en) 2014-05-13 2022-04-25 Bioatla Inc CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS
AU2015280433B2 (en) 2014-06-17 2020-10-08 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102615681B1 (en) 2014-08-28 2023-12-18 바이오아트라, 인코퍼레이티드 Conditionally active chimeric antigen receptors for modified t-cells
MX2017002805A (en) 2014-09-03 2017-12-20 Bioatla Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts.
CN107074969A (en) 2014-09-09 2017-08-18 优努姆治疗公司 Chimerical receptor and its application in immunization therapy
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA2963602A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
WO2016144673A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
JP2018511655A (en) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Immunogenic compositions for use in vaccination against Bordetella
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
BR112017019785B1 (en) 2015-04-13 2022-11-16 Pfizer Inc BISPECIFIC ANTIBODY, ITS USE AND PHARMACEUTICAL COMPOSITION
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR102068915B1 (en) 2015-08-19 2020-01-22 화이자 인코포레이티드 Tissue Factor Pathway Inhibitor Antibodies and Uses thereof
EP4461312A2 (en) 2015-09-15 2024-11-13 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CN108290939B (en) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 Compositions and methods for inhibiting lineage specific antigens
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
TW201936640A (en) 2016-01-21 2019-09-16 美商輝瑞股份有限公司 Antibodies specific for epidermal growth factor receptor variant III and their uses
JP2019512271A (en) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド T cell exhaustion state specific gene expression regulator and use thereof
JP7099967B2 (en) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション Elimination of Proliferative Cells from Stem Cell-Derived Grafts
EP3515559A4 (en) 2016-09-20 2020-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US20190345501A1 (en) 2017-02-07 2019-11-14 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
CA3054885A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
AU2018282759A1 (en) 2017-06-13 2020-01-02 Bostongene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
CA3069179A1 (en) 2017-07-13 2019-01-17 Massachusetts Institute Of Technology Targeting the hdac2-sp3 complex to enhance synaptic function
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
CN113896797B (en) 2017-08-01 2023-05-09 Ab工作室有限公司 Bispecific antibodies and uses thereof
CN111093715A (en) 2017-09-18 2020-05-01 儿童医院医疗中心 Strong insulator and use thereof in gene delivery
WO2019056281A1 (en) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
KR20240023192A (en) 2017-11-24 2024-02-20 유큐(베이징) 바이오파마 코., 엘티디 Anti-OX40 Antibodies and Uses Thereof
WO2019152742A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
WO2019152705A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Antibodies specific for cd70 and their uses
US11912736B2 (en) 2018-02-21 2024-02-27 The University Of Montana Diaryl trehalose compounds and uses thereof
WO2019161536A1 (en) 2018-02-23 2019-08-29 Eucure (Beijing) Biopharma Co. , Ltd Anti-pd-1 antibodies and uses thereof
MX2020008455A (en) 2018-02-28 2021-10-26 Pfizer Il-15 variants and uses thereof.
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
BR112020022595A2 (en) 2018-05-23 2021-02-09 Pfizer Inc. specific antibodies to gucy2c and uses thereof
EP3797121B1 (en) 2018-05-23 2024-06-19 Pfizer Inc. Antibodies specific for cd3 and uses thereof
CN112638402A (en) 2018-07-03 2021-04-09 Sotio有限责任公司 Chimeric receptors in combination with trans-metabolic molecules that enhance glucose import and therapeutic uses thereof
AU2018432434A1 (en) 2018-07-20 2021-01-28 Eucure (Beijing) Biopharma Co., Ltd Anti-CD40 antibodies and uses thereof
KR20210045418A (en) 2018-08-14 2021-04-26 소티오, 엘엘씨 Chimeric antigen receptor polypeptides in combination with trans metabolic molecules that modulate the Krebs cycle and their therapeutic uses
MX2021002415A (en) 2018-08-28 2021-09-21 Vor Biopharma Inc Genetically engineered hematopoietic stem cells and uses thereof.
JP7387743B2 (en) 2018-09-12 2023-11-28 ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド Anti-TNFRSF9 antibody and its use
JP7469305B2 (en) 2018-11-19 2024-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド Anti-PD-1 antibodies and uses thereof
JP7549584B2 (en) 2019-01-23 2024-09-11 ニューヨーク・ユニバーシティ Antibody specific for the delta 1 chain of the T cell receptor
JP2022521358A (en) 2019-02-18 2022-04-06 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド Genetically modified non-human animal with humanized immunoglobulin locus
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
JP2022534038A (en) 2019-05-23 2022-07-27 ザ ユニバーシティー オブ モンタナ Vaccine adjuvants based on TLR receptor ligands
AU2020327680A1 (en) 2019-07-03 2022-01-20 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240092935A1 (en) 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
IL298632A (en) 2020-06-02 2023-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Genetically modified non-human animals with common light chain immunoglobulin locus
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
WO2022120256A2 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US20240158864A1 (en) 2021-01-25 2024-05-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
EP4330969A1 (en) 2021-04-29 2024-03-06 BostonGene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
JP2024528139A (en) 2021-08-02 2024-07-26 ファイザー・インク Improved expression vectors and uses thereof
CA3232833A1 (en) 2021-09-27 2023-03-30 Kathleen Mcginness Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
AU2022388928A1 (en) 2021-11-16 2024-05-16 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
EP4440594A2 (en) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
AU2023221961A1 (en) 2022-02-16 2024-09-26 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
DK3687A (en) * 1986-01-06 1987-07-07 Hoffmann La Roche POLYPEPTIDES AND PROCEDURES FOR PRODUCING THEREOF
AU1391888A (en) * 1987-02-11 1988-09-14 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine

Also Published As

Publication number Publication date
AU4320689A (en) 1991-02-06
NZ229297A (en) 1992-01-29
AP8900126A0 (en) 1989-07-31
AP129A (en) 1991-04-17
EP0345242A3 (en) 1990-05-30
PT90731A (en) 1989-12-29
IL90381A0 (en) 1989-12-15
WO1991000904A1 (en) 1991-01-24
EP0345242A2 (en) 1989-12-06
AU627465B2 (en) 1992-08-27
AU3725689A (en) 1991-01-03

Similar Documents

Publication Publication Date Title
ZA894137B (en) Expression of retrovirus gag protein eukaryotic cells
GB2188639B (en) Expression and purification of an htlv-111 gag/env gene protein
AU587358B2 (en) Control of retroviruses
AU7184487A (en) Human g-csf protein expression
IL89567A0 (en) Mutated hiv envelope protein
NZ224667A (en) Stable human cell lines expressing foreign gene under hiv ltr regulatory control
ZA891355B (en) Expression of hiv binding proteins
IL86251A0 (en) Quantitative determination of lithium
GB8629116D0 (en) Env/gag polypeptides
HUT43873A (en) Rendering of primary cells non-dying
IE891750L (en) Expression of retrovirus gag protein in eukaryotic cells
GB8615681D0 (en) Orthoesters of titanium &c
AU1676288A (en) Human immunodeficiency virus gag-encoded proteins
EP0446272A4 (en) Expression of hiv proteins in -i(drosophila) cells
ZA895967B (en) Activation of target cells
GB8729424D0 (en) Ring beam
IE883483L (en) Expression of hiv proteins
GB2197872B (en) Protein derived from the suprabasal cells of the epidermis
AU7961487A (en) Human enteric coronavirus
AU582574B2 (en) The preparation of polypeptides having human gamma interferon activity
IE891349L (en) EXPRESSION OF THE HIV kDa GAG PROTEIN IN YEAST
IE870677L (en) Preparation of zirconia
CS89788A1 (en) Endoprosthesis of mamma
IE881635L (en) Human immunodeficiency virus gag-encoded proteins
GB8711889D0 (en) Laser preparation of peripheral nerves